Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Shares Outstanding (Entity) came in at $133.7 million in Q2 2026, up 2.1% YoY from $131.0 million in Q2 2025, and little changed on a QoQ basis from $133.4 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Shares Outstanding (Entity) data on file, last reported at $133.7 million in Q2 2026.
- Quarterly Shares Outstanding (Entity) rose 2.1% year-over-year to $133.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $133.7 million (up 2.1% YoY) and the FY2025 annual result came in at $132.4 million, up 2.38% from the prior year.
- Shares Outstanding (Entity) was little changed at $133.7 million in Q2 2026, from $133.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $133.7 million in Q2 2026 to a low of $120.7 million in Q1 2022.
- A 5-year average of $127.5 million and a median of $127.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 3.23% in 2023, down 1.51% in 2023.
- Tracing ALNY's Shares Outstanding (Entity) over 5 years: stood at $123.9 million in 2022, then rose by 1.51% to $125.8 million in 2023, then climbed by 2.78% to $129.3 million in 2024, then grew by 2.38% to $132.4 million in 2025, then climbed by 1.03% to $133.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $133.7 million (Q2 2026), $133.4 million (Q1 2026), and $132.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.61 Mn |
| Mar 31, 2026 | 132.89 Mn |
| Dec 31, 2025 | 131.00 Mn |
| Sep 30, 2025 | 131.45 Mn |
| Jun 30, 2025 | 130.63 Mn |
| Mar 31, 2025 | 129.68 Mn |
| Dec 31, 2024 | 127.65 Mn |
| Sep 30, 2024 | 128.59 Mn |
| Jun 30, 2024 | 126.73 Mn |
| Mar 31, 2024 | 126.14 Mn |
| Dec 31, 2023 | 124.91 Mn |
| Sep 30, 2023 | 125.22 Mn |
| Jun 30, 2023 | 124.66 Mn |
| Mar 31, 2023 | 124.11 Mn |
| Dec 31, 2022 | 121.69 Mn |
| Sep 30, 2022 | 122.17 Mn |
| Jun 30, 2022 | 120.90 Mn |
| Mar 31, 2022 | 120.39 Mn |
| Dec 31, 2021 | 118.45 Mn |
| Sep 30, 2021 | 119.14 Mn |